NASDAQ: BGLCBionexus Gene Lab Corp Stock
$2.50+0.36 (+16.82%)
Updated Jun 15, 2026
BGLC Price
$2.50
Fair Value Price
N/A
Market Cap
$6.04M
52 Week Low
$1.07
52 Week High
$15.60
P/E
-1.68x
P/B
0.75x
P/S
0.98x
PEG
N/A
Dividend Yield
N/A
Revenue
$5.29M
Earnings
-$2.90M
Gross Margin
14.5%
Operating Margin
-54.6%
Profit Margin
-54.9%
Debt to Equity
0.12
Operating Cash Flow
-$1M
Beta
0.07
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BGLC Overview
BioNexus Gene Lab Corp. (BGLC), established in 2017 and headquartered in Kuala Lumpur, Malaysia, conducts business through two primary subsidiaries. Its subsidiary, Chemrex Corporation Sdn. Bhd., specializes in the wholesale distribution of chemical raw material products across Malaysia, Indonesia, Vietnam, and other nations within Southeast Asia. These essential chemicals are utilized in the manufacturing of a wide array of products, including handrails, bench tops, components for the automotive and aerospace industries, cleanroom panels, and various instruments. Additionally, through its other subsidiary, BioNexus Gene Lab Sdn. Bhd., the company is involved in the development and provision of non-invasive liquid biopsy tests, designed for the early detection of biomarkers.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BGLC's potential to beat the market
- BGLC doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Specialty Chemical
Industry Rating
A
BGLC
RankedUnranked of 51
RankedUnranked of 51
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $5.54 | A | |
| $12.97 | A | |
| $44.40 | A |
Be the first to know about important BGLC news, forecast changes, insider trades & much more!
BGLC News
Overview
Due Diligence Score
–
Industry Average (30)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BGLC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BGLC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BGLC is good value based on its book value relative to its share price (0.75x), compared to the US Specialty Chemicals industry average (3.78x)
P/B vs Industry Valuation
BGLC is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more BGLC due diligence checks available for Premium users.
Valuation
BGLC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.68x
Industry
7.33x
Market
14.3x
BGLC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.75x
Industry
3.78x
BGLC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BGLC's financial health
Profit margin
Revenue
$0.0
Net Income
-$543.6k
Profit Margin
0%
BGLC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BGLC's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$9.0M
Liabilities
$946.9k
Debt to equity
0.12
BGLC's short-term assets ($5.20M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BGLC's short-term assets ($5.20M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BGLC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BGLC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$147.7k
Investing
-$14.0k
Financing
$59.7k
BGLC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BGLC vs Specialty Chemical Stocks
Bionexus Gene Lab Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.